Stress-related cognitive and non-cognitive impairments in elderly patients
https://doi.org/10.14412/2074-2711-2015-1-87-93
Abstract
Aging is a physiological process that may develop long without manifestations of comorbidities. In the meantime a high proportion of elderly people very often experience limitations in daily life due to impairments in memory and other cognitive functions. Non-cognitive neuropsychiatric disorders, most commonly stress-related anxiety disorders, are a major contribution to maladaptation in these patients. The present studies of the neurobiology of aging enable one to decipher not only the mechanisms that underlie the physiology of brain aging, but also the factors that influence cognitive aging and aggravate the manifestations of cognitive dysfunction and neurodegenerative disease. The process of brain aging is known to presume the long-term preservation of functional neuroplasticity that is greatly influenced by different lifestyle factors, such as daily social and physical activities, the pattern and amount of food taken, cognitive activity, and stressful life events. These lifestyle factors are supposedly a potent tool to maintain physiological brain aging and a delayed cognitive diminution in elderly people. At the same time, studies of the possibility of pharmacologically correcting age-related (both cognitive and non-cognitive) impairments are promising to improve everyday function in elderly people.
About the Author
G. R. TabeevaRussian Federation
References
1. Mora F, Segovia G, del Arco A. Aging, plasticity and environmental enrichment: structural changes and neurotransmitter dynamics in several areas of the brain. Brain Res Rev. 2007 Aug;55(1):78–88. Epub 2007 Apr 13.
2. Aggarwal NT, Wilson RS, Beck TL, et al. Perceived stress and change in cognitive function among adults aged 65 and older. Psychosom Med. 2014 Jan;76(1):80–5. doi: 10.1097/PSY. 0000000000000016. Epub 2013 Dec 23.
3. Terry RD, Katzman R. Life span and synapses: will there be a primary senile dementia? Neurobiol Aging. 2001 May–Jun;22(3):347–8; discussion 353–4.
4. Mattson MP, Magnus T. Aging and neuronal vulnerability. Nat Rev Neurosci. 2006 Apr;7(4):278–94.
5. Nithianantharajah J, Hannan AJ. Enriched environments, experience dependent plasticity and disorders of the nervous system. Nat Rev Neurosci. 2006 Sep;7(9):697–709.
6. Van Praag H, Kempermann G, Gage FH. Neural consequences of environmental enrichment. Nat Rev Neurosci. 2000 Dec;1(3):191–8.
7. Mora F. Successful brain aging: plasticity, environmental enrichment, and lifestyle. Dialogues Clin Neurosci. 2013 Mar;15(1):45–52.
8. Rolland Y, van Kan GA, Vellas B. Physical activity and Alzheimer’s disease: from prevention to therapeutic perspectives. J Am Med Dir Assoc. 2008 Jul;9(6):390–405. doi: 10.1016/j.jamda.2008.02.007. Epub 2008 Jun 2.
9. Mora F, Segovia G, del Arco A, et al. Stress, neurotransmitters, corticosterone and body-brain integration. Brain Res. 2012 Oct 2;1476:71–85. doi: 10.1016/j.brainres.2011.12.049. Epub 2012 Jan 3.
10. Franz CE, O’Brien RC, Hauger RL, et al. Cross-sectional and 35-year longitudinal assessment of salivary cortisol and cognitive functioning: the Vietnam Era Twin Study of Aging. Psychoneuroendocrinology. 2011 Aug;36(7):1040–52. doi: 10.1016/j.psyneuen. 2011.01.002. Epub 2011 Feb 3.
11. Sapolski RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: glucocorticoid cascade hypothesis. Endocr Rev. 1986 Aug;7(3):284–301.
12. Schultz SK, Moser DJ, Bishop JR, Ellingrod VL. Phobic anxiety in late-life in relationship to cognition and 5HTTLPR polymorphism. Psychiatr Genet. 2005 Dec;15(4):305–6.
13. Forsell Y, Palmer K, Fratiglioni L. Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand Suppl. 2003;179:25–8.
14. Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003 Oct;18(10):951–9.
15. De Luca AK, Lenze EJ, Mulsant BH, et al. Comorbid anxiety disorder in late life depression: association with memory decline over four years. Int J Geriatr Psychiatry. 2005 Sep;20(9):848–54.
16. Feretti L, McCurry S, Logsdon R, et al. Anxiety and Аlzheimer's disease. J Geriatr Psychiatry Neurol. 2001 Spring;14(1):52–8.
17. Palmer K, Berger AK, Monastero R, et al. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007 May 8;68(19):1596–602.
18. Gallacher J, Bayer A, Fish M, et al. Does anxiety affect risk for dementia? Findings from the Caerphilly Prospective Study. Psychosom Med. 2009 Jul;71(6):659–66. doi: 10.1097/PSY. 0b013e3181a6177c. Epub 2009 Jun 24.
19. Schwabe L, Joёls M, Roozendaal B, et al. Stress effects on memory: An update and integration. Neurosci Biobehav Rev. 2012 Aug;36(7):1740–9. doi: 10.1016/j.neubiorev.2011.07.002. Epub 2011 Jul 13.
20. Fuchs E, Czeh B, Kole MH, et al. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S481–90.
21. Qureshi SU, Long ME, Bradshaw MR, et al. Does PTSD impair cognition beyond the effect of trauma? J Neuropsychiatry Clin Neurosci. 2011 Winter;23(1):16–28. doi: 10.1176/appi.neuropsych.23.1.16.
22. Wilson RS, Begeny CT, Boyle PA, et al. Vulnerability to stress, anxiety, and development of dementia in old age. Am J Geriatr Psychiatry. 2011 Apr;19(4):327–34. doi: 10.1097/JGP.0b013e31820119da.
23. Bierman EJM, Comijs HC, Rijmen F, et al. Anxiety symptoms and cognitive performance in later life: results from the longitudinal aging study Amsterdam. Aging Ment Health. 2008 Jul;12(4):517–23. doi: 10.1080/13607860802224276.
24. Gallacher R. Early stage dementia. Nurs Stand. 2014 Jan 15–21;28(20):61. doi: 10.7748/ns2014.01.28.20.61.s50.
25. Burke SN, Barnes CA. Neural plasticity in the ageing brain. Nat Rev Neurosci. 2006 Jan;7(1):30–40.
26. Hedden T, Gabrieli JD. Insights into the aging mind: a view from cognitive neuroscience. Nat Rev Neurosci. 2004 Feb;5(2):87–96.
27. Smith DE, Rapp PR, Mckay HM, et al. Memory impairment in aged primates is associated with focal death of cortical neurons and atrophy of subcortical neurons. J Neurosci. 2004 May 5;24(18):4373–81.
28. Del Arco A, Segovia G, Mora F. Dopamine release Turing stress in the prefrontal cortex of the rat decreases with age. Neuroreport. 2001 Dec 21;12(18):4019–22.
29. Mora F, Segovia G, Del Arco A. Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Brain Res Rev. 2008 Aug;58(2):340–53. Epub 2007 Oct 26.
30. Segovia G, Mora F. Dopamine and GABA increases produced by activation of glutamate receptors in the nucleus accumbens are decreased during aging. Neurobiol Aging. 2005 Jan;26(1):91–101.
31. Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimeris disease. Lancet Neurol. 2011 Feb;10(2):187–98. doi: 10.1016/S14744422(10)70277-5. Epub 2010 Dec 10.
32. Elgh E, Lindqvist Astot A, Fagerlund M, et al. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer’s disease. Biol Psychiatry. 2006 Jan 15;59(2):155–61. Epub 2005 Aug 25.
33. Hartmann A, Veldhuis JD, Deuschle M, et al. Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared withnormal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997 May–Jun;18(3):285–9.
34. Wilson RS, Schneider JA, Boyle PA, et al. Chronic distress and incidence of mild cognitive impairment. Neurology. 2007 Jun 12;68(24):2085–92.
35. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009 Jun;10(6):434–45. doi: 10.1038/nrn2639. Epub 2009 Apr 29.
36. Schubert MI, Kalisch R, Sotiropoulos I, et al. Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure – an in vivo magnetic resonance spectroscopy and imaging study. J Psychiatr Res. 2008 Sep;42(11):902–12. doi: 10.1016/j.jpsychires.2007.10.003. Epub 2008 Jan 3.
37. Catania C, Sotiropoulos I, Silva R, et al. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009 Jan;14(1):95–105. Epub 2007 Oct 2.
38. Green KN, Billings LM, Roozendaal B, et al. Glucocorticoids increase amyloid-beta and TAU pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2006 Aug 30;26(35):9047–56.
39. Sotiropoulos I, Catania C, Pinto LG, et al. Stress acts cumulatively to precipitate Alzheimer’s disease-like tau pathology and cognitive deficits. J Neurosci. 2011 May 25;31(21):7840–7. doi: 10.1523/JNEUROSCI.0730-11.2011.
40. Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens). 2009 Jan–Mar;8(1):7–22.
41. Aggarwal NT, Clark CJ, Beck TL, et al. Perceived stress is associated with subclinical cerebrovascular disease in older adults. Am J Geriatr Psychiatry. 2014 Jan;22(1):53–62. doi: 10.1016/j.jagp.2012.06.001. Epub 2013 Jan 9.
42. Dannlowski U, Stuhrmann A, Beutelmann V, et al. Limbic scars: long-term consequences of childhood maltreatment revealed by functional and structural magnetic resonance imaging. Biol Psychiatry. 2012 Feb 15;71(4):286–93. doi: 10.1016/j.biopsych.2011.10.021. Epub 2011 Nov 23.
43. Милопольская ИМ. Лечение танаканом астенических расстройств. Терапевтический архив. 2001;73(10):45–7. [Milopol'skaya IM. The treatment of asthenic disorders by tanakan. Terapevticheskii arkhiv. 2001;73(10):45–7. (In Russ.)].
44. Porsolt RD, Martin P, Lenegre A, et al. Effects of an extract of Ginkgo biloba (EGb 761) on «learned helplessness» and other models of stress in rodents. Pharmacol Biochem Behav. 1990 Aug;36(4):963–71.
45. Takuma K, Mizoguchi H, Funatsu Y, et al. Placental extract improves hippocampal neuronal loss and fear memory impairment resulting from chronic restraint stress in ovariectomized mice.
46. J Pharmacol Sci. 2012;120(2):89–97.
47. Epub 2012 Sep 6.
48. Landgraf R, Wigger A, Holsboer F, Neumann ID. Hyperreactive hypothalamo-pituitaryadrenocortical axis in rats bred for high anxietyrelated behaviour. J Neuroendocrinol. 1999 Jun;11(6):405–7.
49. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress
50. responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000 Feb;21(1):55–89.
51. Парфенов ВА, Старчина ЮА. Когнитивные расстройства и их лечение у больных артериальной гипертензией. Русский медицинский журнал. 2007;15(2):117–21. [Parfenov VA, Starchina YuA. Cognitive disorders and their treatment in patients with arterial hypertension. Russkii meditsinskii zhurnal. 2007;15(2):117–21. (In Russ.)].
52. Захаров ВВ. Применение танакана при нарушениях памяти и внимания у пожилых. Терапевтический архив. 2002;74(12):95–100. [Zakharov VV. The use of tanakan in memory and attention disorders in older. Terapevticheskii arkhiv. 2002;74(12):95–100. (In Russ.)].
53. DeFeudis FV. Ginkgo biloba extract (EGb 761): from chemistry to the clinic. Wiesbaden: Ullstein-Mosby; 1998. 401 p.
54. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev.
55. ;(4):CD003120.
56. Mancini M, Agozzino B, Bompani R. Clinical and therapeutic effects of Ginkgo biloba extract (GBE) versus placebo in the treatment of psychorganic senile dementia of arteriosclerotic origin. Gazzetta Med Ital 1993;152:69–80.
57. Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014 Nov 28;9:2065–77. doi: 10.2147/CIA.S72728. eCollection 2014.
58. Gavrilova SI, Preuss UW, Wong JWM,
59. et al., and the GIMCIPlus Study Group. Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multicenter trial. Int J Geriatr Psychiatry. 2014 Oct;29(10):1087–95. doi: 10.1002/gps.4103. Epub 2014 Mar 16.
Review
For citations:
Tabeeva G.R. Stress-related cognitive and non-cognitive impairments in elderly patients. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1):87-93. (In Russ.) https://doi.org/10.14412/2074-2711-2015-1-87-93